Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Exosome Diagnostics, Lexogen, Canon BioMedical, More

Exosome Diagnostics MedOncAlyzer 170

Exosome Diagnostics launched the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that interrogates exosomal RNA and circulating tumor DNA in one assay. MedOncalyzer 170 is a targeted panel for tumor profiling that identifies clinically actionable and functionally important mutations across multiple cancer types, using as little as 0.5 ml of patient blood or plasma.


Lexogen Small RNA-seq Library Prep Kit

Lexogen has launched a small RNA-seq library prep kit that is compatible with Illumina's sequencing instruments. Customers can work directly from total RNA or enriched small RNA from a variety of sources, including liquid biopsies, sorted cells, and tissues. In addition, inputs can range from 50 picograms to 1,000 nanograms of RNA. The workflow takes five hours with one hour of hands-on time. The kit comes with up to 96 unique barcodes.


Canon BioMedical Novallele HRM Analyzer

Canon BioMedical has launched the Novallele HRM Analyzer, web-based software capable of analyzing data from different thermocyclers and well plate formats. The software provides an intuitive and easy-to-use graphical interface with comprehensive algorithms capable of analyzing high-resolution melting (HRM) data from different thermocyclers, Canon said. The software also complements Canon's Novallele genotyping assays, in conjunction with the Novallele Controls Sets, to analyze HRM data.


For more new products and services, please visit the New Products page on our website.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.